FLT3 and acute myeloid leukemia: In multivariable analysis that included both clinical and genetic variables, response rates were higher in the presence of NPM1MUT (p < 0.01; OR: 0.41) and lower in the presence of secondary AML (p = 0.03; OR: 1.8), adverse karyotype (p < 0.01; OR: 2.3), TP53MUT (p = 0.04; OR: 1.9), FLT3‐ITDMUT (p < 0.01; OR: 4.8), or RUNX1MUT (p < 0.01; OR: 2.4).